Tuberculosis Diagnostics Market
Tuberculosis Diagnostics Market Forecasts to 2030 - Global Analysis By Product Type (Sputum Smear Microscopy, Culture-Based Diagnostics, Rapid Molecular Diagnostics and Other Product Types), Test Type (Detection of Latent Infection, Radiographic Method, Nucleic Acid Testing, Phage Assay, Diagnostic Laboratory Methods, Detection of Drug Resistance, Cytokine Detection Assay and Other Test Types), Disease Stage , End User and By Geography
|
Years Covered |
2021-2030 |
|
Estimated Year Value (2023) |
US $2.07 BN |
|
Projected Year Value (2030) |
US $3.46 BN |
|
CAGR (2023 - 2030) |
7.6% |
|
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
|
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
|
Largest Market |
Asia Pacific |
|
Highest Growing Market |
North America |
According to Stratistics MRC, the Global Tuberculosis Diagnostics Market is accounted for $2.07 billion in 2023 and is expected to reach $3.46 billion by 2030 growing at a CAGR of 7.6% during the forecast period. Tuberculosis (TB) is a contagious disease caused by Mycobacterium tuberculosis and it mainly attacks the lungs, spine, and brain of the patients. Tuberculosis diagnostics provide objective and precise identification of TB infection. They help differentiate TB from other respiratory diseases with similar symptoms, reducing misdiagnosis and unnecessary treatments.
According to the WHO Global Tuberculosis report 2022, in 2021, approximately 10.6 million individuals fell ill with tuberculosis globally, representing 4.5% rise from 10.1 million cases reported in 2020.
Market Dynamics:
Driver:
Drug-resistant TB
The emergence of drug-resistant strains, such as multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB), has created a need for accurate and rapid diagnostic tests. Drug-resistant TB strains do not respond to the standard first-line anti TB medications, making their detection and appropriate treatment critical. Traditional diagnostic methods may not be effective in identifying drug-resistant strains, leading to delayed or ineffective treatment, increased transmission, and poor patient outcomes. As a result, there is a growing demand for advanced diagnostics that can accurately detect drug-resistant TB.
Restraint:
High cost
Advanced diagnostic technologies, such as molecular tests and genotypic assays, often come with a higher price tag compared to traditional methods like sputum smear microscopy. The cost of these tests includes not only the test kits but also the equipment, laboratory infrastructure, and skilled personnel required for their implementation. Therefore, high costs may deter healthcare providers from implementing more advanced and precise diagnostic techniques, impeding the growth of the market.
Opportunity:
Advanced diagnostic technologies
The utilization of molecular techniques, such as polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs), allows for the detection of TB with enhanced sensitivity, enabling diagnosis even in cases with low bacterial loads. Additionally, improvements in point-of-care testing bring diagnostics closer to the patient. This is especially advantageous in settings with limited resources because it shortens the time between starting treatment and receiving results. Therefore, these advanced diagnostic technologies accelerate market growth.
Threat:
Stigma
Misconceptions regarding the mode of transmission, fear of infection, and associations with poverty or marginalized groups are some of the factors that contribute to the stigma surrounding tuberculosis. However, this stigma can lead to reluctance among individuals to disclose their symptoms, seek healthcare, or undergo TB diagnostic testing. People may be unable to receive TB diagnostic services because of fear of social exclusion, discrimination, or unfavourable societal perceptions. This can postpone diagnosis and contribute to the disease's spread. These factors hamper market demand.
Covid-19 Impact
The COVID-19 pandemic has had a significant impact on the tuberculosis diagnostics market. While it initially disrupted healthcare systems, diverting resources away from TB diagnostics, it also highlighted the importance of robust diagnostic infrastructure. Long-term benefits for TB diagnostics could result from increased awareness of the need for strengthening healthcare systems as the pandemic fades. Furthermore, COVID-19 may have accelerated advancements in telemedicine and digital health, which could improve the capacity for tuberculosis diagnosis.
The diagnostic laboratory methods segment is expected to be the largest during the forecast period
The diagnostic laboratory methods segment is estimated to hold the largest share. Most hospitals and clinics globally provide culture-based tests as well as smear microscopy. Due to this, they are a viable choice for tuberculosis diagnosis for patients who might not have access to more sophisticated diagnostic procedures. Moreover, while newer tests, such as nucleic acid amplification tests (NAATs), are becoming more widely available, smear microscopy and culture-based tests are still considered to be the most accurate tests for diagnosing tuberculosis.
The sputum smear microscopy segment is expected to have the highest CAGR during the forecast period
The sputum smear microscopy segment is anticipated to have lucrative growth during the forecast period. It is a simple and cost-effective technique used to detect acid-fast bacilli (AFB) in sputum samples, aiding in the diagnosis of pulmonary TB. Sputum smear microscopy is widely available, even in resource-limited settings, as it does not require sophisticated laboratory infrastructure or expensive equipment. Moreover, it provides rapid results, enabling healthcare providers to initiate TB treatment promptly, reducing transmission, and improving patient outcomes.
Region with largest share:
Asia Pacific dominated the market and accounted for the largest market share due to its high burden as well as the rapid proliferation of this disease. The rising rates of tuberculosis in several of the countries in this region are one of the primary drivers of the increase in market revenue. Furthermore, the high mortality rate and low human development index in this region are important factors that support the growth in market revenue. Bangladesh, China, India, Indonesia, Pakistan, and the Philippines are among the affected nations in this region.
Region with highest CAGR:
North America is expected to witness profitable growth over the projection period, owing to the rising prevalence of tuberculosis among adults and children. Medical research institutes in this region are discovering an increasing number of benefits associated with pathogen-specific metabolic pathways. This could serve as a substitute for the existing techniques that focus on the detection of pathogen immune responses, bacterial growth, or bacterial nucleic acid amplification. Additionally, AI and nanotechnology combined significantly aid in improving the tuberculosis diagnosis process among patients in North America.
Key players in the market
Some of the key players in the Tuberculosis Diagnostics Market include Becton Dickinson and Company, Qiagen NV, Thermo Fisher Scientific Inc., Oxford Immunotec Ltd., Hoffmann-La Roche Ltd., Hologic Inc., BioMerieux SA, Akonni Biosystems Inc., Cepheid Inc., Alere Inc., PAR Pharmaceuticals, Hain Life Science and Lionex GmbH.
Key Developments:
In February 2022 – QIAGEN announced that its QuantiFERON tuberculosis testing solution received the approval of the fourth generation of a modern gold standard test in China.
In March 2022, Thermo Fisher Scientific Inc. launched the SeqStudio Flex Series Genetic Analyzer for research & development of infectious disease detection, which is expected to expand the company's product portfolio in the market.
Product Types Covered:
• Sputum Smear Microscopy
• Culture-Based Diagnostics
• Rapid Molecular Diagnostics
• Other Product Types
Test Types Covered:
• Detection of Latent Infection
• Radiographic Method
• Nucleic Acid Testing
• Phage Assay
• Diagnostic Laboratory Methods
• Detection of Drug Resistance
• Cytokine Detection Assay
• Other Test Types
Disease Stages Covered:
• Active Tuberculosis
• Latent Tuberculosis
End Users Covered:
• Physician’s Office Laboratories
• Hospitals and Diagnostic Laboratories
• Reference Laboratories
• Academics and Research Facilities
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Tuberculosis Diagnostics Market, By Product Type
5.1 Introduction
5.2 Sputum Smear Microscopy
5.3 Culture-Based Diagnostics
5.4 Rapid Molecular Diagnostics
5.5 Other Product Types
6 Global Tuberculosis Diagnostics Market, By Test Type
6.1 Introduction
6.2 Detection of Latent Infection
6.3 Radiographic Method
6.4 Nucleic Acid Testing
6.5 Phage Assay
6.6 Diagnostic Laboratory Methods
6.7 Detection of Drug Resistance
6.8 Cytokine Detection Assay
6.9 Other Test Types
7 Global Tuberculosis Diagnostics Market, By Disease Stage
7.1 Introduction
7.2 Active Tuberculosis
7.3 Latent Tuberculosis
8 Global Tuberculosis Diagnostics Market, By End User
8.1 Introduction
8.2 Physician’s Office Laboratories
8.3 Hospitals and Diagnostic Laboratories
8.4 Reference Laboratories
8.5 Academics and Research Facilities
8.6 Other End Users
9 Global Tuberculosis Diagnostics Market, By Geography
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 Italy
9.3.4 France
9.3.5 Spain
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 New Zealand
9.4.6 South Korea
9.4.7 Rest of Asia Pacific
9.5 South America
9.5.1 Argentina
9.5.2 Brazil
9.5.3 Chile
9.5.4 Rest of South America
9.6 Middle East & Africa
9.6.1 Saudi Arabia
9.6.2 UAE
9.6.3 Qatar
9.6.4 South Africa
9.6.5 Rest of Middle East & Africa
10 Key Developments
10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies
11 Company Profiling
11.1 Becton Dickinson and Company
11.2 Qiagen NV
11.3 Thermo Fisher Scientific Inc.
11.4 Oxford Immunotec Ltd.
11.5 Hoffmann-La Roche Ltd.
11.6 Hologic Inc.
11.7 BioMerieux SA
11.8 Akonni Biosystems Inc.
11.9 Cepheid Inc.
11.10 Alere Inc.
11.11 PAR Pharmaceuticals
11.12 Hain Life Science.
11.13 Lionex GmbH
List of Tables
1 Global Tuberculosis Diagnostics Market Outlook, By Region (2021-2030) ($MN)
2 Global Tuberculosis Diagnostics Market Outlook, By Product Type (2021-2030) ($MN)
3 Global Tuberculosis Diagnostics Market Outlook, By Sputum Smear Microscopy (2021-2030) ($MN)
4 Global Tuberculosis Diagnostics Market Outlook, By Culture-Based Diagnostics (2021-2030) ($MN)
5 Global Tuberculosis Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2021-2030) ($MN)
6 Global Tuberculosis Diagnostics Market Outlook, By Other Product Types (2021-2030) ($MN)
7 Global Tuberculosis Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
8 Global Tuberculosis Diagnostics Market Outlook, By Detection of Latent Infection (2021-2030) ($MN)
9 Global Tuberculosis Diagnostics Market Outlook, By Radiographic Method (2021-2030) ($MN)
10 Global Tuberculosis Diagnostics Market Outlook, By Nucleic Acid Testing (2021-2030) ($MN)
11 Global Tuberculosis Diagnostics Market Outlook, By Phage Assay (2021-2030) ($MN)
12 Global Tuberculosis Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2021-2030) ($MN)
13 Global Tuberculosis Diagnostics Market Outlook, By Detection of Drug Resistance (2021-2030) ($MN)
14 Global Tuberculosis Diagnostics Market Outlook, By Cytokine Detection Assay (2021-2030) ($MN)
15 Global Tuberculosis Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
16 Global Tuberculosis Diagnostics Market Outlook, By Disease Stage (2021-2030) ($MN)
17 Global Tuberculosis Diagnostics Market Outlook, By Active Tuberculosis (2021-2030) ($MN)
18 Global Tuberculosis Diagnostics Market Outlook, By Latent Tuberculosis (2021-2030) ($MN)
19 Global Tuberculosis Diagnostics Market Outlook, By End User (2021-2030) ($MN)
20 Global Tuberculosis Diagnostics Market Outlook, By Physician’s Office Laboratories (2021-2030) ($MN)
21 Global Tuberculosis Diagnostics Market Outlook, By Hospitals and Diagnostic Laboratories (2021-2030) ($MN)
22 Global Tuberculosis Diagnostics Market Outlook, By Reference Laboratories (2021-2030) ($MN)
23 Global Tuberculosis Diagnostics Market Outlook, By Academics and Research Facilities (2021-2030) ($MN)
24 Global Tuberculosis Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
25 North America Tuberculosis Diagnostics Market Outlook, By Country (2021-2030) ($MN)
26 North America Tuberculosis Diagnostics Market Outlook, By Product Type (2021-2030) ($MN)
27 North America Tuberculosis Diagnostics Market Outlook, By Sputum Smear Microscopy (2021-2030) ($MN)
28 North America Tuberculosis Diagnostics Market Outlook, By Culture-Based Diagnostics (2021-2030) ($MN)
29 North America Tuberculosis Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2021-2030) ($MN)
30 North America Tuberculosis Diagnostics Market Outlook, By Other Product Types (2021-2030) ($MN)
31 North America Tuberculosis Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
32 North America Tuberculosis Diagnostics Market Outlook, By Detection of Latent Infection (2021-2030) ($MN)
33 North America Tuberculosis Diagnostics Market Outlook, By Radiographic Method (2021-2030) ($MN)
34 North America Tuberculosis Diagnostics Market Outlook, By Nucleic Acid Testing (2021-2030) ($MN)
35 North America Tuberculosis Diagnostics Market Outlook, By Phage Assay (2021-2030) ($MN)
36 North America Tuberculosis Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2021-2030) ($MN)
37 North America Tuberculosis Diagnostics Market Outlook, By Detection of Drug Resistance (2021-2030) ($MN)
38 North America Tuberculosis Diagnostics Market Outlook, By Cytokine Detection Assay (2021-2030) ($MN)
39 North America Tuberculosis Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
40 North America Tuberculosis Diagnostics Market Outlook, By Disease Stage (2021-2030) ($MN)
41 North America Tuberculosis Diagnostics Market Outlook, By Active Tuberculosis (2021-2030) ($MN)
42 North America Tuberculosis Diagnostics Market Outlook, By Latent Tuberculosis (2021-2030) ($MN)
43 North America Tuberculosis Diagnostics Market Outlook, By End User (2021-2030) ($MN)
44 North America Tuberculosis Diagnostics Market Outlook, By Physician’s Office Laboratories (2021-2030) ($MN)
45 North America Tuberculosis Diagnostics Market Outlook, By Hospitals and Diagnostic Laboratories (2021-2030) ($MN)
46 North America Tuberculosis Diagnostics Market Outlook, By Reference Laboratories (2021-2030) ($MN)
47 North America Tuberculosis Diagnostics Market Outlook, By Academics and Research Facilities (2021-2030) ($MN)
48 North America Tuberculosis Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
49 Europe Tuberculosis Diagnostics Market Outlook, By Country (2021-2030) ($MN)
50 Europe Tuberculosis Diagnostics Market Outlook, By Product Type (2021-2030) ($MN)
51 Europe Tuberculosis Diagnostics Market Outlook, By Sputum Smear Microscopy (2021-2030) ($MN)
52 Europe Tuberculosis Diagnostics Market Outlook, By Culture-Based Diagnostics (2021-2030) ($MN)
53 Europe Tuberculosis Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2021-2030) ($MN)
54 Europe Tuberculosis Diagnostics Market Outlook, By Other Product Types (2021-2030) ($MN)
55 Europe Tuberculosis Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
56 Europe Tuberculosis Diagnostics Market Outlook, By Detection of Latent Infection (2021-2030) ($MN)
57 Europe Tuberculosis Diagnostics Market Outlook, By Radiographic Method (2021-2030) ($MN)
58 Europe Tuberculosis Diagnostics Market Outlook, By Nucleic Acid Testing (2021-2030) ($MN)
59 Europe Tuberculosis Diagnostics Market Outlook, By Phage Assay (2021-2030) ($MN)
60 Europe Tuberculosis Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2021-2030) ($MN)
61 Europe Tuberculosis Diagnostics Market Outlook, By Detection of Drug Resistance (2021-2030) ($MN)
62 Europe Tuberculosis Diagnostics Market Outlook, By Cytokine Detection Assay (2021-2030) ($MN)
63 Europe Tuberculosis Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
64 Europe Tuberculosis Diagnostics Market Outlook, By Disease Stage (2021-2030) ($MN)
65 Europe Tuberculosis Diagnostics Market Outlook, By Active Tuberculosis (2021-2030) ($MN)
66 Europe Tuberculosis Diagnostics Market Outlook, By Latent Tuberculosis (2021-2030) ($MN)
67 Europe Tuberculosis Diagnostics Market Outlook, By End User (2021-2030) ($MN)
68 Europe Tuberculosis Diagnostics Market Outlook, By Physician’s Office Laboratories (2021-2030) ($MN)
69 Europe Tuberculosis Diagnostics Market Outlook, By Hospitals and Diagnostic Laboratories (2021-2030) ($MN)
70 Europe Tuberculosis Diagnostics Market Outlook, By Reference Laboratories (2021-2030) ($MN)
71 Europe Tuberculosis Diagnostics Market Outlook, By Academics and Research Facilities (2021-2030) ($MN)
72 Europe Tuberculosis Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
73 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Country (2021-2030) ($MN)
74 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Product Type (2021-2030) ($MN)
75 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Sputum Smear Microscopy (2021-2030) ($MN)
76 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Culture-Based Diagnostics (2021-2030) ($MN)
77 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2021-2030) ($MN)
78 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Other Product Types (2021-2030) ($MN)
79 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
80 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Detection of Latent Infection (2021-2030) ($MN)
81 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Radiographic Method (2021-2030) ($MN)
82 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Nucleic Acid Testing (2021-2030) ($MN)
83 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Phage Assay (2021-2030) ($MN)
84 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2021-2030) ($MN)
85 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Detection of Drug Resistance (2021-2030) ($MN)
86 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Cytokine Detection Assay (2021-2030) ($MN)
87 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
88 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Disease Stage (2021-2030) ($MN)
89 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Active Tuberculosis (2021-2030) ($MN)
90 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Latent Tuberculosis (2021-2030) ($MN)
91 Asia Pacific Tuberculosis Diagnostics Market Outlook, By End User (2021-2030) ($MN)
92 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Physician’s Office Laboratories (2021-2030) ($MN)
93 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Hospitals and Diagnostic Laboratories (2021-2030) ($MN)
94 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Reference Laboratories (2021-2030) ($MN)
95 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Academics and Research Facilities (2021-2030) ($MN)
96 Asia Pacific Tuberculosis Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
97 South America Tuberculosis Diagnostics Market Outlook, By Country (2021-2030) ($MN)
98 South America Tuberculosis Diagnostics Market Outlook, By Product Type (2021-2030) ($MN)
99 South America Tuberculosis Diagnostics Market Outlook, By Sputum Smear Microscopy (2021-2030) ($MN)
100 South America Tuberculosis Diagnostics Market Outlook, By Culture-Based Diagnostics (2021-2030) ($MN)
101 South America Tuberculosis Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2021-2030) ($MN)
102 South America Tuberculosis Diagnostics Market Outlook, By Other Product Types (2021-2030) ($MN)
103 South America Tuberculosis Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
104 South America Tuberculosis Diagnostics Market Outlook, By Detection of Latent Infection (2021-2030) ($MN)
105 South America Tuberculosis Diagnostics Market Outlook, By Radiographic Method (2021-2030) ($MN)
106 South America Tuberculosis Diagnostics Market Outlook, By Nucleic Acid Testing (2021-2030) ($MN)
107 South America Tuberculosis Diagnostics Market Outlook, By Phage Assay (2021-2030) ($MN)
108 South America Tuberculosis Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2021-2030) ($MN)
109 South America Tuberculosis Diagnostics Market Outlook, By Detection of Drug Resistance (2021-2030) ($MN)
110 South America Tuberculosis Diagnostics Market Outlook, By Cytokine Detection Assay (2021-2030) ($MN)
111 South America Tuberculosis Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
112 South America Tuberculosis Diagnostics Market Outlook, By Disease Stage (2021-2030) ($MN)
113 South America Tuberculosis Diagnostics Market Outlook, By Active Tuberculosis (2021-2030) ($MN)
114 South America Tuberculosis Diagnostics Market Outlook, By Latent Tuberculosis (2021-2030) ($MN)
115 South America Tuberculosis Diagnostics Market Outlook, By End User (2021-2030) ($MN)
116 South America Tuberculosis Diagnostics Market Outlook, By Physician’s Office Laboratories (2021-2030) ($MN)
117 South America Tuberculosis Diagnostics Market Outlook, By Hospitals and Diagnostic Laboratories (2021-2030) ($MN)
118 South America Tuberculosis Diagnostics Market Outlook, By Reference Laboratories (2021-2030) ($MN)
119 South America Tuberculosis Diagnostics Market Outlook, By Academics and Research Facilities (2021-2030) ($MN)
120 South America Tuberculosis Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
121 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Country (2021-2030) ($MN)
122 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Product Type (2021-2030) ($MN)
123 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Sputum Smear Microscopy (2021-2030) ($MN)
124 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Culture-Based Diagnostics (2021-2030) ($MN)
125 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Rapid Molecular Diagnostics (2021-2030) ($MN)
126 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Other Product Types (2021-2030) ($MN)
127 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Test Type (2021-2030) ($MN)
128 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Detection of Latent Infection (2021-2030) ($MN)
129 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Radiographic Method (2021-2030) ($MN)
130 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Nucleic Acid Testing (2021-2030) ($MN)
131 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Phage Assay (2021-2030) ($MN)
132 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Diagnostic Laboratory Methods (2021-2030) ($MN)
133 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Detection of Drug Resistance (2021-2030) ($MN)
134 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Cytokine Detection Assay (2021-2030) ($MN)
135 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Other Test Types (2021-2030) ($MN)
136 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Disease Stage (2021-2030) ($MN)
137 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Active Tuberculosis (2021-2030) ($MN)
138 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Latent Tuberculosis (2021-2030) ($MN)
139 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By End User (2021-2030) ($MN)
140 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Physician’s Office Laboratories (2021-2030) ($MN)
141 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Hospitals and Diagnostic Laboratories (2021-2030) ($MN)
142 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Reference Laboratories (2021-2030) ($MN)
143 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Academics and Research Facilities (2021-2030) ($MN)
144 Middle East & Africa Tuberculosis Diagnostics Market Outlook, By Other End Users (2021-2030) ($MN)
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
